The main objective of present work was to prepare a solid SEDDS for enhancement of oral bioavailability of Valsartan, poorly water soluble drug. The solubility of the drug was determined in various vehicles. A pseudo ternary phase diagram was constructed to identify the self-micro emulsification region. Further, the resultant formulations were investigated for clarity, phase separation, globule size, effect of pH and dilutions and freeze-thaw stability. The optimized SMEDDS (F4) formulation of Valsartan contained Capmul MCM (Oil), Kolliphor HS 15 (Surfactant) and PEG 400 (Co-surfactant). This optimized formulation was converted in to solid SEDDS by adding required quantity of Neusilin US2 as adsorbing agent used for in vitro dissolution and bioavailability assessment. The oral bioavailability of Valsartan from solid SEDDS was 1.6-fold higher compared to that of Valsartan suspension in rats, suggesting a significant increase (p < 0.05) in oral bioavailability of Valsartan from solid SEDDS
